Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Blueprint Medicines Corp shares valued at $159,407 were sold by Haviland Kate on Jan 21 ’25. At $110.24 per share, Haviland Kate sold 1,446 shares. The insider’s holdings dropped to 149,378 shares worth approximately $17.08 million following the completion of this transaction.
Also, Rossi Christina sold 2,274 shares, netting a total of over 250,455 in proceeds. Following the sale of shares at $110.14 each, the insider now holds 67,109 shares.
Before that, Albers Jeffrey W. had sold 15,161 shares from its account. In a trade valued at $1,660,511, the Director traded Blueprint Medicines Corp shares for $109.53 each. Upon closing the transaction, the insider’s holdings decreased to 15,161 shares, worth approximately $17.42 million.
As published in their initiating research note from JP Morgan on November 14, 2024, Blueprint Medicines Corp [BPMC] has been an Overweight and the price target has been revised to $126. Analysts at UBS started covering the stock with ‘”a Neutral”‘ outlook in a report released in late October. As of May 14, 2024, Stephens has initiated its “an Overweight” rating for BPMC. Earlier on May 06, 2024, Leerink Partners upgraded its rating. Their new recommendation was “a Market perform” for BPMC stock which previously was a “an Underperform”.
Analyzing BPMC Stock Performance
During the last five days, there has been a surge of approximately 2.92%. Over the course of the year, Blueprint Medicines Corp shares have jumped approximately 31.07%. Shares of the company reached a 52-week high of $118.25 on 01/27/25 and a 52-week low of $86.72 on 01/10/25. A 50-day SMA is recorded $96.88, while a 200-day SMA reached $97.78. Nevertheless, trading volume fell to 0.65 million shares from 0.43 million shares the previous day.
Support And Resistance Levels for Blueprint Medicines Corp (BPMC)
According to the 24-hour chart, there is a support level at 112.97, which, if violated, would cause prices to drop to 111.62. In the upper region, resistance lies at 116.38. The next price resistance is at 118.44. RSI (Relative Strength Index) is 69.85 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 7.14, which suggests the price will increase in the coming days. Percent R is at 12.46%, indicating bullish price movement. Stochastics %K at selling indicates that the stock is to be held.
